[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Garvan Institute of Medical Research · St Vincent's Hospital Sydney · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
146
total citations
- FWCI
- 54.52
- Percentile
- 100%
- References
- 27
Citations per year
Authors
39- LELouise EmmettCorresponding
Garvan Institute of Medical Research, St Vincent's Hospital Sydney, St Vincent's Clinic, UNSW Sydney
- SSShalini Subramaniam
University of Sydney, National Health and Medical Research Council, Bankstown Lidcombe Hospital
- MCMegan Crumbaker
The Kinghorn Cancer Centre, Macquarie University, Garvan Institute of Medical Research, St Vincent's Hospital Sydney, St Vincent's Clinic, UNSW Sydney
- ANAndrew Nguyen
St Vincent's Hospital Sydney, St Vincent's Clinic, UNSW Sydney
- AMAnthony M. Joshua
Garvan Institute of Medical Research, The Kinghorn Cancer Centre, St Vincent's Hospital Sydney
Topics & keywords
Topics
Keywords
- Enzalutamide
- Medicine
- Prostate cancer
- Docetaxel
- Oncology
- Internal medicine
- Clinical endpoint
- Abiraterone acetate
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.